GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...
The monarchE trial's primary overall survival (OS) analysis presented at ESMO 2025 confirms that 2 years of ...
GSK’s Blenrep receives US FDA approval to treat relapsed/refractory multiple myeloma: London, UK Saturday, October 25, 2025, 11:00 Hrs [IST] GSK plc announced the US Food and Dr ...
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...
GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...
Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination regimen, the ...
CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.
The FDA approved of Blenrep in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback